Welcome to our dedicated page for Sana Biotechnology SEC filings (Ticker: SANA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sana Biotechnology鈥檚 engineered-cell breakthroughs are exciting鈥攜et their regulatory filings can feel like advanced immunology textbooks. Clinical trial updates, gene-editing methods and cash-runway calculations are scattered across hundreds of pages, leaving analysts asking how to extract the essentials before the market moves.
Stock Titan solves that problem. Our AI reads every Sana Biotechnology quarterly earnings report 10-Q filing and annual report 10-K simplified, then delivers plain-English takeaways on pipeline progress and balance-sheet strength. Need real-time alerts? We push Sana Biotechnology Form 4 insider transactions real-time so you can track executive stock transactions Form 4 the moment they post. From a sudden 8-K material events explained to a detailed proxy statement executive compensation table, we keep the entire library鈥�10-K, 10-Q, 8-K, S-1, DEF 14A鈥攗pdated within minutes of hitting EDGAR.
Whether you鈥檙e monitoring Sana Biotechnology insider trading Form 4 transactions for confidence signals, comparing R&D spend through Sana Biotechnology earnings report filing analysis, or simply understanding Sana Biotechnology SEC documents with AI, our platform turns technical language into actionable context. Find every HIP platform disclosure, follow funding milestones, and answer natural questions like 鈥淪ana Biotechnology SEC filings explained simply鈥� without wading through PDFs. Critical biotech data, delivered clearly鈥攕o you can focus on decisions, not document hunts.
Oxford Square Capital Corp. (NASDAQ: OXSQ) has released its 2025 Definitive Proxy Statement ahead of the 20 August 2025 Annual Meeting at its Greenwich, CT headquarters.
- Proposals: (1) election of Barry A. Osherow as the sole Class II director (term expiring 2028); (2) ratification of PricewaterhouseCoopers LLP (PwC) as independent auditor for FY-2025.
- Board structure: five-member, staggered board; 60% classified as independent. Steven P. Novak continues as Independent Chairman.
- Ownership: Directors & officers collectively hold 6.53 million shares (8.6 % of 76.0 million outstanding). CEO Jonathan H. Cohen and affiliated entities own 3.0 %, making him the largest individual insider.
- Auditor fees: PwC audit fees declined to $947,995 in 2024 from $1.08 million in 2023; no tax or other fees were incurred.
- Compensation: Independent directors earn a base $90,000 plus committee/board chair retainers and meeting fees; no equity awards are granted.
- Governance highlights: Four fully independent committees (Audit, Valuation, Nominating & Governance, Compensation) oversee risk, valuation, and advisor oversight. The Investment Advisory Agreement with Oxford Square Management was renewed on 22 April 2025 after the board reviewed fees, performance and adviser profitability.
- Quorum & voting: record date 25 June 2025; majority of outstanding shares (38.0 million) required for a quorum. Brokers may vote only on Proposal 2.
The board unanimously recommends voting FOR both proposals. No other substantive matters are scheduled.
Sana Biotechnology, Inc. (NASDAQ: SANA) filed a Form 8-K to disclose a material scientific milestone. On June 23 2025, the company announced positive six-month results from an investigator-sponsored, first-in-human study evaluating UP421鈥攁n allogeneic primary islet cell therapy engineered with Sana鈥檚 proprietary hypoimmune technology鈥攊n a patient with type 1 diabetes. Notably, the transplant was performed without any immunosuppression, underscoring a key differentiator of the platform. The announcement was furnished as Exhibit 99.1 to the report and no other financial metrics, earnings data or transactions were included.
The filing is limited to Item 8.01 (Other Events) and Item 9.01 (Exhibits). It confirms that the press release dated June 23 2025 is now part of the public record. No changes to guidance, capitalization or management were reported. The disclosure highlights continued progress of Sana鈥檚 cell-engineering pipeline and potentially de-risks the hypoimmune approach, but investors must await fuller clinical datasets before drawing definitive efficacy or commercial conclusions.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
What is the primary focus of Sana Biotechnology?
How does Sana Biotechnology utilize its HIP platform?
Which therapeutic areas does Sana Biotechnology target?
How does Sana Biotechnology differentiate itself from competitors?
What are the key components of Sana Biotechnology's business model?
What types of cell therapies are under development at Sana Biotechnology?
How does Sana Biotechnology approach clinical development?
Who can benefit from Sana Biotechnology's therapies?
